Agilent Technologies, Inc.

DUBLIN--( BUSINESS WIRE )--The "Bioprocess Optimization and Digital Bio-manufacturing: Global Markets" report has been added to ResearchAndMarkets.com's offering. The Global Bioprocess Optimization and Digital Bio-manufacturing Market was valued at USD 24.3 Billion in 2024, and is expected to reach USD 39.6 Billion by 2029, rising at a CAGR of 10.20%. The report provides a comprehensive analysis of the bioprocess optimization and digital biomanufacturing market in a global context, including market forecasts and sales through the year 2029. Segmentation based on technology type includes manufacturing technologies (chromatography-based separation and purification, filtration, bioreactors, centrifugation), analytical and process control technologies (spectrophotometry, automation and industrial process control technologies, analytical chromatography, sensors and probes), and software (Industrial control and automation software, bioprocess optimization and data analytics software). Segmentation based on application includes biomanufacturing process automation and control, flexible manufacturing, bioprocess optimization and process analytics, and others. By molecule type the market is segmented into monoclonal antibodies, vaccines, therapeutic proteins and peptides, and cell and gene therapies. The regional markets covered are North America, Europe, Asia-Pacific, and the Rest of the World (RoW). The report discusses the critical issues impacting the adoption of digital biomanufacturing in pharmaceuticals, as well as emerging trends in digital biomanufacturing technologies. It also features new developments and new product launches in the global market. The report provides comprehensive profiles of market players in the industry. The report also covers mergers and acquisitions and any other collaborations or partnerships that occurred during the evaluation period of this report and which are expected to shape the industry. Report Scope 69 data tables and 61 additional tables Analyses of trends in the global market for bioprocess optimization and digital bio-manufacturing, with market revenue data for 2021-2023, estimates for 2024, forecasts for 2025, and projected CAGRs through 2029 Estimates of the market size and revenue growth prospects of the global market, along with a market share analysis by technology, application, drug molecule type and region Facts and figures pertaining to the market dynamics, technical advances, regulations and the impact of macroeconomic factors Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses Analysis of patents, emerging trends, and new developments Analysis of the industry structure, including companies' market shares, strategic alliances, M&A activity and a venture funding outlook Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and ESG scores and practices of leading companies Profiles of the market leaders, including Agilent Technologies Inc., Thermo Fisher Scientific Inc., Danaher Corp., and Sartorius AG. Key Attributes: Report Attribute Details No. of Pages 180 Forecast Period 2024 - 2029 Estimated Market Value (USD) in 2024 $24.3 Billion Forecasted Market Value (USD) by 2029 $39.6 Billion Compound Annual Growth Rate 10.2% Regions Covered Global Key Topics Covered: Chapter 1 Introduction Market Outlook Scope of Report Market Summary Chapter 2 Market Overview Technology Background Biologics Manufacturing Process Upstream Processing Cell Harvesting and Clarification Downstream Processing Bioprocess Optimization Industry 4.0 - Digital Biomanufacturing Chapter 3 Market Dynamics Market Drivers Growing Aging Population Increasing Prevalence of Chronic Diseases Unprecedented Rise in Demand for Biopharmaceuticals Growing Number of Product Launches Increasing Number of Contract Manufacturing Organizations (CMOs) Market Restraints Lack of Skilled Labor High Cost of Equipment Unharmonized Smart Manufacturing Standards Market Opportunities Favorable Government Programs Advances in Sensor Technology Process Analytical Technology Initiatives Market Challenges Technical Issues and the Threat of Cyberattacks Regulatory Landscape Good Automation Manufacturing Practices (GAMP) Instrumentation, Systems, and Automation (ISA) Society-88 and 95 Standards Chapter 4 Emerging Technologies and Developments Emerging Trends and Technologies Continuous Bioprocessing Continuous Cell Retention Technologies Continuous Chromatography Single-Use Technologies Chapter 5 Market Segmentation Analysis Market Analysis by Technology Manufacturing Technologies Analytical and Process Control Technologies Software Market Analysis by Application Biomanufacturing Process Automation and Control Flexible Manufacturing Bioprocess Optimization and Process Analytics Other Applications Market Analysis by Molecule Type Monoclonal Antibodies (mAbs) Therapeutic Proteins and Peptides Vaccines Cell and Gene Therapies Market Analysis by Region Chapter 6 Competitive Intelligence Ranking of Leading Players Key Strategies Adopted by Players Collaborations and Partnerships Expansion Acquisitions New Product Launches Chapter 7 Sustainability in the Bioprocess Optimization and Digital Biomanufacturing Market: An ESG Perspective ESG Practices in the Industry Companies' ESG Risk Ratings Company Profiles Agilent Technologies Agilitech Bio-Rad Laboratories Bruker Clean Biologics Danaher Emerson Electric Eppendorf Korber Merck Sartorius Shimadzu Thermo Fisher Scientific Univercells Technologies Waters For more information about this report visit https://www.researchandmarkets.com/r/vlkua2 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

DUBLIN--( BUSINESS WIRE )--The "DNA Sequencing: Research, Applied and Clinical Markets" report has been added to ResearchAndMarkets.com's offering. The Global DNA Sequencing Market was valued at USD 14.8 Billion in 2024, and is expected to reach USD 34.8 Billion by 2029, rising at a CAGR of 18.60%. The report highlights the current and future market potential of DNA sequencing and provides a detailed analysis of market drivers, restraints and opportunities. The report also gives market projections for 2029 and includes a competitive environment and product analysis. The report provides market estimates and forecasts for DNA sequencing based on technology, product & service, end user, application, disease category, and region. By technology, the market is segmented into next-generation sequencing (NGS), third-generation sequencing (TGS), pyrosequencing, and Sanger sequencing. By product and service, the market is categorized into instruments and consumables or services. By end user, the market is segmented into academic and research institutes, hospitals and clinics, pharmaceutical and biotechnology companies, contract research organizations, and others. By application, the market is categorized as biopharma, microbiology, agriculture, or others. By disease category, the market is segmented into cancer, reproductive health, Mendelian disorders, and others. The report includes the company profiles of the key players, with detailed information about their business segments, financials, product portfolios, and recent developments. By geographical region, the market has been segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). The North American region includes the U.S., Canada and Mexico. Europe includes Germany, the U.K., Italy, France, Spain, and the Rest of Europe; Asia-Pacific includes China, Japan, India, Australia, South Korea, and the Rest of Asia-Pacific. For market estimates, data has been provided for 2021 and 2022 as the historic years and for 2023 as the base year, with forecasts through 2029. Report Scope 70 data tables and 59 additional tables An overview of the global market for DNA sequencing technologies and their applications in research, applied and clinical segments Analysis of the global market trends, with data from 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029 A market forecast for the DNA sequencing industry, and a corresponding market share analysis by products and services, end-use segment, application, disease category and region A look at the key market dynamics for DNA sequencing, and the regulatory scenario Discussion of market opportunities for DNA sequencing, industry structure, applications and business considerations of sequencing technologies, along with the ongoing changes in the structure of the MedTech industry Review of the leading next-generation sequencing (NGS) technologies, emerging applications, and the DNA sequencing-based diagnostics and research initiatives affecting the market Analysis of patents related to novel sequencing technologies, as well as clinical trials A discussion of ESG challenges and ESG practices in the industry Insights into the major acquisitions and strategic alliances, competitive benchmarking of sequencing industry participants and their growth strategies Market share analysis of the leading companies, as well as company profiles, including Illumina Inc., Thermo Fisher Scientific Inc., Pacific Biosciences (PacBio), and Oxford Nanopore Technologies Ltd. Key Attributes: Report Attribute Details No. of Pages 168 Forecast Period 2024 - 2029 Estimated Market Value (USD) in 2024 $14.8 Billion Forecasted Market Value (USD) by 2029 $34.8 Billion Compound Annual Growth Rate 18.6% Regions Covered Global Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Insights Chapter 2 Market Overview Importance of DNA Genetic Variation and Analysis History of Sequencing NGS (Second-generation Sequencing) TGS (Long-read Sequencing) Research and Applied Applications R&D Applications Applied Applications Direct to Consumer Biopharma Agriculture Forensics Microbiome Synthetic Biology Chapter 3 Market Dynamics Market Drivers Technological Advances in Sequencing Techniques Rising Applications of DNA Sequencing in Clinical Diagnostics Market Restraints High Cost of DNA Sequencing Data Interpretation and Management Challenges Market Opportunities Expansion of Precision Medicine Growth in NIPT Chapter 4 Emerging Technologies Long-read Sequencing Technologies SMRT Sequencing Nanopore Sequencing Spatial Genomics and Transcriptomics Single-cell DNA Sequencing Ultra-low Input Sequencing CRISPR-Cas9 and Genome-editing Integration with Sequencing Technologies AI and Machine Learning in DNA Sequencing Chapter 5 Market Segmentation Analysis Global DNA Sequencing Market Analysis by Product and Service Instruments and Consumables Services Global DNA Sequencing Market Analysis by Technology NGS TGS Sanger Sequencing Pyrosequencing Global DNA Sequencing Market Analysis by Application Biopharma Microbiology Agriculture Others (Synthetic Biology, Population Genomics, and Consumer Genomics) Global DNA Sequencing Market Analysis by End User Market Size and Forecast Academic and Research Institutes Hospitals and Clinics Pharmaceutical and Biotechnology Companies Clinical Research Others (Agricultural Institutions, Forensic Labs) Global DNA Sequencing Market Analysis by Disease Category Market Size and Forecast Cancer Reproductive Health Mendelian Disorders Others (Cardiology, Metabolic/Immune, Neurology, Transplant, Clinical) Geographic Breakdown Chapter 6 Competitive Landscape Partnerships Investments and Funding Patent Analysis Chapter 7 ESG Perspective ESG Performance in the Market ESG Practices in the DNA Sequencing Industry Environmental Performance Social Performance Governance Performance ESG Risk Ratings in the DNA Sequencing Industry Companies Featured Agilent Technologies BGI F. Hoffman-La Roche Guardant Health Illumina Myriad Genetics Oxford Nanopore Technologies PACBIO Qiagen Thermo Fisher Scientifc For more information about this report visit https://www.researchandmarkets.com/r/fbdff8 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Cellworks Group, Inc. , a leader in Personalized Therapy Decision Support and Precision Drug Development, today announced that its computational laboratory in Franklin, Tennessee, has obtained certification of compliance from the Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA). This certification authorizes the lab to perform personalized therapy biosimulation for cancer patients within the U.S. Cellworks' CLIA-certified biosimulation platform meets the rigorous standards required for clinical use, providing oncologists with a powerful tool to guide personalized treatment decisions and improve patient care. The platform leverages a mechanistic Computational Biosimulation Model (CBM) that uses genomic aberrations from a patient's cancer tumor to predict response to specific therapies. By combining mechanistic biology modeling, machine learning, and statistical analysis, the platform delivers patient-specific therapy response predictions to support treatment decisions. "We are proud that our computational biosimulation lab has earned CLIA certification," said Yatin Mundkur , CEO of Cellworks. "This milestone underscores our commitment to uphold the highest standards of laboratory practice. CLIA certification validates the clinical reliability of our biosimulation platform and also enables us to participate in federal healthcare programs such as Medicare and Medicaid, broadening access to our innovative solutions. It marks a pivotal step in our mission to advance Personalized Therapy Decision Support and improve outcomes for cancer patients." "CLIA certification exemplifies the stringent quality standards upheld by our laboratory, ensuring accuracy, reliability and precision,” said Dr. Michael J. Donovan , PhD, MD, Laboratory Director at Cellworks. “This achievement highlights our dedication to providing oncologists and their patients with clinically validated tools they can trust. We look forward to collaborating with oncologists to deliver innovative personalized therapeutic response predictions that have the potential to positively impact patients’ lives.” The Cellworks Platform The Cellworks Platform performs computational biosimulation of protein-protein interactions, enabling in silico modeling of tumor behavior using comprehensive genomic data. This allows for the evaluation of how personalized treatment strategies interact with the patient’s unique tumor network. Multi-omic data from an individual patient or cohort is used as input to the in silico Cellworks Computational Biology Model (CBM) to generate a personalized or cohort-specific disease model. The CBM is a highly curated mechanistic network of 6,000+ human genes, 30,000 molecular species and 600,000 molecular interactions. This model along with associated drug models are used to biosimulate the impact of specific compounds or combinations of drugs on the patient or cohort and produce therapy response predictions, which are statistically modeled to produce a qualitative Therapy Response Index (TRI) score, scaled from 0 (unfavorable outcome) to 100 (favorable outcome) for a specific therapy. The Cellworks CBM has been tested and applied against various clinical datasets with results provided in over 125 presentations and publications with global collaborators. About Cellworks Group Cellworks Group, Inc. is a leader in Personalized Therapy Decision Support and Precision Drug Development. The Cellworks Platform predicts therapy response for individual patients and patient cohorts using a breakthrough Computational Biology Model (CBM) and biosimulation technology. Backed by Artiman Ventures, Bering Capital, Sequoia Capital, UnitedHealth Group and Agilent Ventures, Cellworks has the world’s strongest trans-disciplinary team of molecular biologists, cellular pathway modelers and software engineers working toward a common goal – attacking serious diseases to improve the lives of patients. The company is based in South San Francisco, California with a CLIA-certified computational laboratory in Franklin, Tennessee and a research and development facility in Bangalore, India. For more information, visit cellworks.life . All trademarks and registered trademarks in this document are the properties of their respective owners.